Vertex Pharmaceuticals Aktie News

December's mixed performance for tech may be an early signal that leadership is narrowing, especially among the value-stretched stocks. Investors looking forward to 2026 may find better risk-adjusted opportunities in defensive sectors with select growth drivers. Rather than relying solely on traditional names, this article digs deeper into Quant Strong Buys that combine durable cash flows, esse...

Microsoft shares underperformed due to concerns about its relationship with OpenAI following the Oracle/OpenAI deal announcement. Vertex Pharmaceuticals lost value following disappointing clinical trial results in one of its pain therapy programs. We initiated a position in Advanced Micro Devices (AMD), a leading provider of high-performance computing and AI solutions.

There are only 12 investing days left in 2025. Now is a great time to load up on stocks that may win next year -- and over time.

CRISPR Therapeutics could soar on the back of significant pipeline progress next year. Vertex's slow and steady approach to diversifying its lineup should eventually pay off.

Apple's fiercely loyal customer base gives it a built-in market for any new devices it might launch in the future. MercadoLibre is positioned to grow rapidly in the Latin America e-commerce and fintech markets.

Vertex Pharmaceuticals is the worldwide leader in cystic fibrosis treatment -- and its drugs have generated blockbuster revenue. The company has expanded into other therapeutic areas in recent years and has won approval for treatments for blood disorders and pain management.

Vertex Pharmaceuticals said on Saturday its gene therapy helped children aged between 5 and 11 years with sickle cell disease to be free of painful events and allowed those with another blood disorder that requires frequent blood transfusions to be transfusion-free for at least 12 consecutive months.

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal ...